Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 12/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29332485 | 0.91 | S1PR5 (0.60) | S1PR5GRIN2BGRIN1SIGMAR1HTR1A | |
| SCHEMBL20573749 | 0.86 | S1PR5 (0.58) | S1PR5GRIN2BSIGMAR1 | |
| SCHEMBL19201157 | 0.85 | S1PR5 (0.75) | S1PR5SIGMAR1HTR1ADRD2HTR2A | |
| SCHEMBL20573754 | 0.84 | S1PR5 (0.98) | S1PR5GRIN2B | |
| SCHEMBL20573457 | 0.84 | S1PR5 (1.00) | S1PR5GRIN2B | |
| SCHEMBL20573747 | 0.83 | S1PR5 (1.00) | S1PR5 | |
| SCHEMBL29332477 | 0.82 | S1PR5 (0.74) | S1PR5GRIN2BSIGMAR1 | |
| SCHEMBL20573441 | 0.81 | S1PR5 (1.00) | S1PR5 | |
| SCHEMBL19201158 | 0.76 | S1PR5 (1.00) | S1PR5 | |
| SCHEMBL20573684 | 0.76 | S1PR5 (0.86) | S1PR5HTR1ADRD2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409658-B9 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3409658-B9 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3409658-B1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-10730830-B2 | Tetrahydronaphthalene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-04 | — | — | US | disclosed |
| US-10730830-B2 | Tetrahydronaphthalene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-04 | — | — | US | disclosed |
| US-20190031605-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20190031605-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3409658-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017131149-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | 小野薬品工業株式会社 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730830-B2 | Tetrahydronaphthalene derivative | S1PR5, S1PR1, GPR55 | S1PR5 1/4885GRIN2B 297/4885GRIN1 180/4885 |
| US-20190031605-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | S1PR5, S1PR1, GPR55 | S1PR5 1/4885GRIN2B 413/4885GRIN1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.